Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Greenway Greenhouse Cannabis EV-to-EBITDA?
Greenway Greenhouse CannabisGWAYF EV-to-EBITDA is 46.54 as of Aug. 05, 2026. The stock has 4 warning signs investors should review. Among 745 Drug Manufacturers companies, Greenway Greenhouse Cannabis ranks worse than 88.32% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Greenway Greenhouse Cannabis's enterprise value is $18.34 Mil.
Greenway Greenhouse Cannabis's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $0.39 Mil. Therefore, Greenway Greenhouse Cannabis's EV-to-EBITDA for today is 46.54.
The historical rank and industry rank for Greenway Greenhouse Cannabis's EV-to-EBITDA or its related term are showing as below:
GWAYF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1377.99 Med: -32.7 Max: 70.41
Current: 47.14
During the past 6 years, the highest EV-to-EBITDA of Greenway Greenhouse Cannabis was 70.41. The lowest was -1377.99. And the median was -32.70.
GWAYF's EV-to-EBITDA is ranked worse than 88.32% of 745
companies
in the Drug Manufacturers industry
Industry Median: 13.04
vs GWAYF: 47.14
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Greenway Greenhouse Cannabis's PE Ratio (TTM) for today is calculated as:
Greenway Greenhouse Cannabis's share price for today is $0.0628.
Greenway Greenhouse Cannabis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Greenway Greenhouse Cannabis's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Greenway Greenhouse Cannabis EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Greenway Greenhouse Cannabis's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Greenway Greenhouse Cannabis's EV-to-EBITDA falls into.
Greenway Greenhouse Cannabis's current Enterprise Value is $18.34 Mil.
Greenway Greenhouse Cannabis's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Greenway Greenhouse Cannabis (GWAYF) has a EV-to-EBITDA of 46.54 as of Aug. 05, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Greenway Greenhouse Cannabis. According to the industry distribution chart, Greenway Greenhouse Cannabis ranks #658 out of 745 companies in the Drug Manufacturers industry, placing it in the top 88.3%.
Is Greenway Greenhouse Cannabis' EV-to-EBITDA too high?
Greenway Greenhouse Cannabis' current EV-to-EBITDA is 46.54. The Drug Manufacturers industry median EV-to-EBITDA is 13.04. Greenway Greenhouse Cannabis' value of 46.54 is 256.9% above this industry median. Based on the distribution chart, Greenway Greenhouse Cannabis ranks #658 out of 745 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Greenway Greenhouse Cannabis' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Greenway Greenhouse Cannabis ranks #658 out of 745 companies for EV-to-EBITDA. This places Greenway Greenhouse Cannabis in the lower half of its industry. The industry median EV-to-EBITDA is 13.04. Greenway Greenhouse Cannabis' value of 46.54 is 256.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.04, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Greenway Greenhouse Cannabis's current EV-to-EBITDA of 46.54 is 256.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Greenway Greenhouse Cannabis. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Greenway Greenhouse Cannabis's current EV-to-EBITDA is 46.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenway Greenhouse Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Greenway Greenhouse Cannabis (GWAYF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.06 — trading 70.1% below its estimated fair value. The current EV-to-EBITDA is 46.54 and 256.9% above the Drug Manufacturers industry median of 13.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Greenway Greenhouse Cannabis (GWAYF), the current EV-to-EBITDA is 46.54 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Greenway Greenhouse Cannabis Corp is licensed to cultivate, process and sell to ensures harvests always consist of the highest quality cannabis strains with resinous flowers, trichomes, and rich cannabinoid profiles. The Company's nursery facility is located in Kingsville, Ontario, and its flowering and processing facility is located in Leamington, Ontario. The business model is to supply bulk packaged, high quality cannabis to the Canadian, cannabis industry at prices that ultimately provide a value proposition to the consumers. Greenway has three divisions with various locations; Greenway Nursery, Greenway Cultivation and future plans for Greenway Farmgate Retail Store.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GWAYF has been successfully added to your 
